HealthQuad, the growth venture arm of Quadria Group focused on healthcare innovation, has announced its latest investment in LifeSigns, an AI-powered remote patient monitoring platform. The investment reflects HealthQuad’s focus on supporting next-generation healthcare models that shift care delivery from episodic and reactive treatment to continuous and predictive healthcare intelligence.

The partnership comes at a time when healthcare systems globally are facing increasing pressure from rising patient demand, workforce shortages and escalating costs. Continuous patient monitoring and early clinical intervention are emerging as critical capabilities in improving patient outcomes and operational efficiency. LifeSigns is leveraging artificial intelligence to create a predictive care layer that identifies early signs of patient deterioration, enabling timely clinical decisions and improving survival outcomes.

As LifeSigns’ first institutional investor, HealthQuad will support the company not only with capital but also through access to Quadria’s global healthcare ecosystem. The collaboration will focus on expanding LifeSigns’ presence in Southeast Asia and the Gulf Cooperation Council (GCC) region, while also strengthening its AI-led technology capabilities through selective integrations and product development initiatives.

HealthQuad Fund III, the successor to its earlier funds, aims to back category-defining healthcare companies building scalable and globally relevant solutions. Rahul Agarwal, Partner at HealthQuad, said the future of healthcare lies in continuous monitoring and predictive intelligence rather than periodic observation. He noted that LifeSigns is building a globally relevant platform capable of significantly improving patient outcomes while reducing healthcare costs through early risk detection and intervention.

Hari Subramaniam, Founder and CEO, LifeSigns, said the company was founded on the belief that no patient should deteriorate silently due to inadequate monitoring systems. He added that the platform has already demonstrated clinical impact and scalability in India, and the partnership with HealthQuad and Quadria would help expand the predictive care model globally.

The global remote patient monitoring devices market is estimated at USD 26 billion in 2025, driven by the healthcare industry’s shift toward decentralised and continuous monitoring models. LifeSigns has developed an integrated US FDA-approved monitoring platform that combines a medical-grade wearable device, cloud-based dashboard and predictive AI engine. The platform is designed for use across ambulances, emergency rooms, intensive care units, hospital wards and home-care settings.

The solution continuously monitors critical health parameters including ECG, heart rate, respiration, temperature, blood pressure and oxygen saturation. According to the company, its AI engine can detect early signs of deterioration up to 26 hours in advance and identify critical risks within a four-hour window, enabling proactive medical intervention.

LifeSigns currently operates across more than 50 hospitals in India and has generated over 87,000 life-saving alerts. The company claims its platform has helped reduce code blue incidents by nearly 90 percent and lowered ICU readmissions by close to 78 percent. Its central monitoring command centre also enables scalable remote surveillance, helping healthcare providers address operational and workforce challenges more effectively.